Autolus Lifts Aucatzyl Outlook to $150 Million After Q3 Revenue Doubles

By Grace Kim

Autolus Therapeutics raised its full-year Aucatzyl revenue floor to at least $150 million on Nov. 6's third-quarter call, after quarterly net product revenue nearly doubled to $41.2 million from $21.1 million a year earlier. The biotech's previous guidance range was $140 million to $150 million for combined U.S. and U.K. sales; its initial projection, set earlier in the year, ran $120 million to $135 million.

First-nine-months Aucatzyl revenue reached $113.1 million, up 122% year over year. CEO Christian Itin said the U.K. launch was progressing well, with U.K. sales to be broken out separately at full-year results.

In plain terms: the launch is beating plan, and management just paid for it with a higher floor.

What's driving the margin improvement?

Numbers first. Third-quarter gross margin hit 57%, up from 55% in Q2 and from negative territory a year ago. Nine-month gross margin stands at 44%.

CFO Rob Dolski attributed the swing to lower manufacturing costs per batch, higher production volumes, operational efficiencies, and reduced inventory reserves and write-offs. Cost of sales fell to $17.9 million from $28.6 million.

Itin expects Autolus to manufacture more than twice as many products in 2026 as in 2025 — with fewer staff. He framed the outlook as continued efficiency gains rather than step changes, and said the company anticipates approaching the top of its indicated 65% to 70% gross margin range (revenue left after production costs) in 2028.

Where do the losses and cash stand?

The net loss narrowed to $55.1 million from $79.1 million a year earlier, and the operating loss fell to $43.5 million from $71.6 million. Research and development spending rose to $30.9 million from $27.9 million on higher clinical manufacturing supply costs; selling, general and administrative expenses were $35.9 million, slightly below last year's $36.3 million.

Cash, cash equivalents and marketable securities totaled $248.4 million at Sept. 30, up from $201.6 million at the end of June. Dolski credited financing from a credit facility with Perceptive Advisors, including an initial $75 million tranche. The company expects its resources to fund operations into Q2 2028, assuming anticipated sales and a second $25 million tranche.

Short version: losses are shrinking, the balance sheet grew, and the runway now stretches to mid-2028.

How fast is the treatment-center network growing?

Autolus has authorized 90 treatment centers in the U.S. and 18 in the U.K. It hit its goal of 80 active U.S. centers in the third quarter — a target it had set for all of 2026.

Itin said roughly 80 U.S. centers already cover about 80% of patients. Expansion will now target access gaps, follow physicians establishing CAR T therapy (a treatment that engineers a patient's immune cells to fight cancer) at new sites, and include selected non-academic centers with substantial patient flows.

On Q4, Itin said sales levels have been similar across the second, third and fourth quarters of 2025, and that the holidays can slow dosing — particularly between Christmas and New Year's — though the impact was limited last year. He also flagged upcoming real-world Aucatzyl data from the ROCCA consortium as a potential adoption driver, while cautioning that third- and fourth-year sales growth typically trails the jump between years one and two.

Why did the multiple sclerosis data slip?

Autolus will present initial data from its BOBCAT study in progressive multiple sclerosis at ECTRIMS in October 2027, not the March meeting. Clinical experts advised that at least 12 months of follow-up is needed to begin interpreting disability scores, with 24 months preferable, Itin said.

By October 2027, the company expects 12 patients with at least 12 months of follow-up and another 12 with six to 12 months. The study was expanded from 18 to 24 patients to build a larger dataset across two preconditioning regimens. Itin called bendamustine potentially less hematologically toxic than fludarabine and cyclophosphamide, though it's known to be a weaker preconditioning agent in leukemia and lymphoma. He said the study remains on track and the timing doesn't change development decision-making.

What clinical data is coming next?

Longer-term follow-up from the phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus showed sustained clinical responses and a stable safety profile out to 25 months, with presentation scheduled at the ACR meeting the day of the call. Itin said safety-related news in the autoimmune cell therapy field during the second half hasn't visibly dented enrollment.

The LUMINA study in refractory lupus nephritis continues enrolling, and CATULUS in pediatric acute lymphoblastic leukemia should complete enrollment around end-2026 or early 2027. At ASH, Autolus expects additional Aucatzyl data in adult relapsed or refractory acute lymphoblastic leukemia, plus initial AUTO8 data in light-chain amyloidosis covering patients treated with both BCMA- and CD19-targeting components.

The bottom line for finance desks: revenue is compounding, margins are on a visible path toward 65-70%, and the cash runway now covers the story into 2028.